Factors Associated with Real-World Multitarget Stool DNA Test Adherence and Follow-up Colonoscopy Completion in a California Healthcare System
Journal of Health Economics and Outcomes Research · 19.11.2026 · 13 (2)
DOI: 10.36469/001c.172785 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Health Economics and Outcomes Research, online erschienen am 19.11.2026. Verfasst von Ora Karp Gordon und 6 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Colorectal cancer (CRC) is highly treatable when diagnosed early, but screening benefit depends on completing both initial testing and follow-up colonoscopy (FU-CY) after a positive stool-based test.
Objectives
As quality measurements increasingly emphasize FU-CY after positive noninvasive CRC screening results, this study evaluated factors associated with multitarget stool DNA (mt-sDNA) adherence and FU-CY completion within the Providence Healthcare System in California.
Methods
This retrospective cohort study linked laboratory data from Abbott with administrative claims data from Komodo Health. The study population included mt-sDNA tests shipped to patients between July 2016 and June 2023. Adherence was defined as return of a completed test with a valid result within one year of shipment. Completion of FU-CY was defined as the first eligible colonoscopy claim occurring within 1 year of a positive mt-sDNA result. Multivariable logistic regression was used to identify factors associated with mt-sDNA adherence. Among test kits with a positive mt-sDNA finding, factors associated with time to FU-CY were evaluated using Cox proportional hazards regression.
Results
Of 6191 mt-sDNA test kits, 4766 (77.0%) were completed within 1 year. Higher adjusted odds of adherence were observed among males, among patients with commercial, Medicare Advantage, or traditional Medicare insurance compared with Medi-Cal; among patients with prior mt-sDNA use; among gastroenterologist-ordered tests; and among those receiving full digital or SMS-only outreach. Among 560 patients with positive mt-sDNA results, who met the continuous enrollment requirement, 394 (70.4%) completed FU-CY within 1 year. Gastroenterologist-ordered tests were associated with shorter time to FU-CY completion (adjusted hazard ratio, 2.26; 95% CI, 1.31-3.88).
Discussion
High mt-sDNA screening adherence and FU-CY completion were observed in this California-based Providence cohort, although adherence varied across patient and healthcare delivery characteristics. These results suggest that both demographic and healthcare delivery factors influence the effectiveness of screening programs.
Conclusions
These findings suggest that modifiable healthcare delivery strategies, including digital reminders, and coordinated follow-up pathways, may support participation and diagnostic continuity in stool-based CRC screening programs.
Zitieren
APA
Gordon, O. K., Mahashabde, R., Aranda, G., Arroyo, J., Pan, J. Y., Karlitz, J. J., & Greene, M. (2026). Factors Associated with Real-World Multitarget Stool DNA Test Adherence and Follow-up Colonoscopy Completion in a California Healthcare System. Journal of Health Economics and Outcomes Research, 13(2). https://doi.org/10.36469/001c.172785
Vancouver
Gordon OK, Mahashabde R, Aranda G, Arroyo J, Pan JY, Karlitz JJ, et al. Factors Associated with Real-World Multitarget Stool DNA Test Adherence and Follow-up Colonoscopy Completion in a California Healthcare System. Journal of Health Economics and Outcomes Research. 2026;13(2). doi:10.36469/001c.172785
BibTeX
@article{Gordon2026,
author = {Gordon, Ora Karp and Mahashabde, Ruchira and Aranda, Gustavus and Arroyo, Jeffrey and Pan, Jennifer Yi-Jiun and Karlitz, Jordan J. and Greene, Mallik},
title = {Factors Associated with Real-World Multitarget Stool DNA Test Adherence and Follow-up Colonoscopy Completion in a California Healthcare System},
journal = {Journal of Health Economics and Outcomes Research},
year = {2026},
volume = {13},
number = {2},
doi = {10.36469/001c.172785}
}
EUVIMED